Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

BUY
$17.78 - $42.39 $1,440 - $3,433
81 Added 29.03%
360 $9,000
Q4 2021

Feb 03, 2022

SELL
$47.84 - $64.34 $2,248 - $3,023
-47 Reduced 14.42%
279 $16,000
Q3 2021

Nov 05, 2021

BUY
$59.27 - $95.73 $8,297 - $13,402
140 Added 75.27%
326 $19,000
Q1 2021

May 03, 2021

BUY
$72.16 - $117.4 $1,587 - $2,582
22 Added 13.41%
186 $15,000
Q4 2020

Feb 04, 2021

SELL
$38.09 - $100.95 $12,417 - $32,909
-326 Reduced 66.53%
164 $15,000
Q3 2020

Nov 02, 2020

BUY
$30.41 - $40.5 $2,432 - $3,240
80 Added 19.51%
490 $20,000
Q1 2019

Apr 26, 2019

SELL
$13.15 - $18.71 $1,841 - $2,619
-140 Reduced 25.45%
410 $7,000
Q4 2018

Feb 05, 2019

BUY
$11.48 - $16.98 $6,314 - $9,339
550 New
550 $7,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $136M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.